Covid-19 Vaccine Trial: Johnson & Johnson halts Coronavirus vaccine trial due to unexplained illness

By: |
October 13, 2020 8:13 AM

The New Brunswick, New Jersey-based company said in a statement late Monday the participant’s illness is being evaluated, and that it would share more information after further investigation.

J&J’s setback is the latest reality check for a world anxiously awaiting a vaccine against the virus, which has sickened more than 37 million globally. (Representational image: Reuters)

Johnson & Johnson said its Covid-19 vaccine study has been temporarily halted after a clinical trial participant experienced an unexplained illness, the second time that a front-runner developer has paused a trial amid the intensifying race to create a viable immunization against the virus.

The New Brunswick, New Jersey-based company said in a statement late Monday the participant’s illness is being evaluated, and that it would share more information after further investigation. J&J’s statement confirmed an earlier report by health-care news provider STAT that the study was paused.

“We are committed to providing transparent updates throughout the clinical development process of our vaccine candidate,” J&J said in its statement. “Adverse events – illnesses, accidents, etc. – even those that are serious, are an expected part of any clinical study, especially large studies.”

While pauses in late-stage testing are routine in the pharmaceutical industry, J&J’s interruption may contribute to concerns over safety with Covid-19 vaccine research progressing at an unprecedented speed this year. British drugmaker AstraZeneca Plc last month temporarily stopped tests of its own vaccine candidate after a trial participant fell ill. That study has resumed in a number of countries, but remains halted in the U.S.

J&J executives will likely face questions about the trial halt Tuesday morning U.S. time when they present third-quarter earnings. Representatives for the U.S. Food and Drug Administration could not immediately be reached by phone or email for comment after business hours.

The Keys to Speed in Race for Vaccine, and Its Perils: QuickTake

J&J’s setback is the latest reality check for a world anxiously awaiting a vaccine against the virus, which has sickened more than 37 million globally. It’s a reminder of how long it takes to bring a successful shot to market, despite promises from politicians and governments that a Covid-19 fix is around the corner.

The pursuit of a vaccine has become a political topic, with some observers concerned that U.S. President Donald Trump’s eagerness to see a shot authorized before the election could compromise the scientific process.

While there are hundreds of Covid-19 vaccines being developed around the world, J&J is among a small group of vaccine makers which have progressed into final-stage human studies. The company is dosing up to 60,000 volunteers in the first big trial of an Covid-19 inoculation that may work after just one shot.

The Drugs and Vaccines That Might End the Coronavirus Pandemic

AstraZeneca is still waiting for a decision from U.S. regulators on whether it can resume tests in the country after halting global trials on Sept. 6 due to concerns about a U.K. participant who became ill. Developed with Oxford University, that experimental vaccine has seen trials resume outside the U.S. in locations including the U.K. and South Africa.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covid-19: Delta Plus is now variant of concern in India
2Delta variant of coronavirus more transmissible, more dangerous, says US Surgeon General Dr Vivek Murthy
3Coronavirus pandemic: Centre classifies Delta Plus as variant of concern, issues advisory to affected states